A population-based case-control teratologic study of nalidixic acid

E. Czeizel, H. T. Sørensen, J. Olsen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Quinolones, mainly nalidixic acid, are frequently used in Hungary to treat bacterial infections in pregnant women, but so far no controlled epidemiological studies of congenital abnormalities among infants born to women treated with nalidixic acid during pregnancy have been reported. Methods: The analysis of oral nalidixic acid use during pregnancy in the mothers of cases with congenital abnormalities and in their matched population controls without congenital abnormality was carried out in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996. The study included 22865 women who had newborns or fetuses with congenital abnormalities, and 38151 pregnant women who had newborn infants without any defects (controls). Results: In the case group, 242 (1.1%) and in the control group, 377 (1.0%) pregnant women were treated with nalidixic acid (crude OR: 1.1 with 95% CI: 0.9-1.3). Seventeen different congenital abnormality groups were evaluated and a higher prevalence of pyloric stenosis was found in seven case infants born to mothers who received nalidixic acid treatment during the last months of pregnancy (adjusted OR: 11.0 with 95% CI: 1.3-91.4). Conclusions: Treatment with nalidixic acid during pregnancy may increase the risk of pyloric stenosis, though the chance effects cannot be excluded.

Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalInternational Journal of Gynecology and Obstetrics
Volume73
Issue number3
DOIs
Publication statusPublished - Jun 2001

Fingerprint

Nalidixic Acid
Case-Control Studies
Pyloric Stenosis
Population
Pregnant Women
Pregnancy
Mothers
Newborn Infant
Population Control
Hungary
Quinolones
Bacterial Infections
Epidemiologic Studies
Fetus
Control Groups
Therapeutics

Keywords

  • Case-control analysis
  • Congenital abnormalities
  • Human teratogenic potential
  • Nalidixic acid
  • Pyloric stenosis

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

A population-based case-control teratologic study of nalidixic acid. / Czeizel, E.; Sørensen, H. T.; Olsen, J.

In: International Journal of Gynecology and Obstetrics, Vol. 73, No. 3, 06.2001, p. 221-228.

Research output: Contribution to journalArticle

@article{2b5d6ceb0ca140bf8e327af629e5e100,
title = "A population-based case-control teratologic study of nalidixic acid",
abstract = "Objective: Quinolones, mainly nalidixic acid, are frequently used in Hungary to treat bacterial infections in pregnant women, but so far no controlled epidemiological studies of congenital abnormalities among infants born to women treated with nalidixic acid during pregnancy have been reported. Methods: The analysis of oral nalidixic acid use during pregnancy in the mothers of cases with congenital abnormalities and in their matched population controls without congenital abnormality was carried out in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996. The study included 22865 women who had newborns or fetuses with congenital abnormalities, and 38151 pregnant women who had newborn infants without any defects (controls). Results: In the case group, 242 (1.1{\%}) and in the control group, 377 (1.0{\%}) pregnant women were treated with nalidixic acid (crude OR: 1.1 with 95{\%} CI: 0.9-1.3). Seventeen different congenital abnormality groups were evaluated and a higher prevalence of pyloric stenosis was found in seven case infants born to mothers who received nalidixic acid treatment during the last months of pregnancy (adjusted OR: 11.0 with 95{\%} CI: 1.3-91.4). Conclusions: Treatment with nalidixic acid during pregnancy may increase the risk of pyloric stenosis, though the chance effects cannot be excluded.",
keywords = "Case-control analysis, Congenital abnormalities, Human teratogenic potential, Nalidixic acid, Pyloric stenosis",
author = "E. Czeizel and S{\o}rensen, {H. T.} and J. Olsen",
year = "2001",
month = "6",
doi = "10.1016/S0020-7292(01)00345-9",
language = "English",
volume = "73",
pages = "221--228",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A population-based case-control teratologic study of nalidixic acid

AU - Czeizel, E.

AU - Sørensen, H. T.

AU - Olsen, J.

PY - 2001/6

Y1 - 2001/6

N2 - Objective: Quinolones, mainly nalidixic acid, are frequently used in Hungary to treat bacterial infections in pregnant women, but so far no controlled epidemiological studies of congenital abnormalities among infants born to women treated with nalidixic acid during pregnancy have been reported. Methods: The analysis of oral nalidixic acid use during pregnancy in the mothers of cases with congenital abnormalities and in their matched population controls without congenital abnormality was carried out in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996. The study included 22865 women who had newborns or fetuses with congenital abnormalities, and 38151 pregnant women who had newborn infants without any defects (controls). Results: In the case group, 242 (1.1%) and in the control group, 377 (1.0%) pregnant women were treated with nalidixic acid (crude OR: 1.1 with 95% CI: 0.9-1.3). Seventeen different congenital abnormality groups were evaluated and a higher prevalence of pyloric stenosis was found in seven case infants born to mothers who received nalidixic acid treatment during the last months of pregnancy (adjusted OR: 11.0 with 95% CI: 1.3-91.4). Conclusions: Treatment with nalidixic acid during pregnancy may increase the risk of pyloric stenosis, though the chance effects cannot be excluded.

AB - Objective: Quinolones, mainly nalidixic acid, are frequently used in Hungary to treat bacterial infections in pregnant women, but so far no controlled epidemiological studies of congenital abnormalities among infants born to women treated with nalidixic acid during pregnancy have been reported. Methods: The analysis of oral nalidixic acid use during pregnancy in the mothers of cases with congenital abnormalities and in their matched population controls without congenital abnormality was carried out in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996. The study included 22865 women who had newborns or fetuses with congenital abnormalities, and 38151 pregnant women who had newborn infants without any defects (controls). Results: In the case group, 242 (1.1%) and in the control group, 377 (1.0%) pregnant women were treated with nalidixic acid (crude OR: 1.1 with 95% CI: 0.9-1.3). Seventeen different congenital abnormality groups were evaluated and a higher prevalence of pyloric stenosis was found in seven case infants born to mothers who received nalidixic acid treatment during the last months of pregnancy (adjusted OR: 11.0 with 95% CI: 1.3-91.4). Conclusions: Treatment with nalidixic acid during pregnancy may increase the risk of pyloric stenosis, though the chance effects cannot be excluded.

KW - Case-control analysis

KW - Congenital abnormalities

KW - Human teratogenic potential

KW - Nalidixic acid

KW - Pyloric stenosis

UR - http://www.scopus.com/inward/record.url?scp=0035370369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035370369&partnerID=8YFLogxK

U2 - 10.1016/S0020-7292(01)00345-9

DO - 10.1016/S0020-7292(01)00345-9

M3 - Article

VL - 73

SP - 221

EP - 228

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 3

ER -